Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 14Genitourinary 5Breast 5Thoracic 2Gastrointestinal 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Prostatic Neoplasms 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia 1Glioblastoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Flow Cytometry 3Psychiatric Rehabilitation 2Methylprednisolone 2Immunologic Techniques 2Azacitidine 2Alemtuzumab 2trametinib 1sargramostim 1ruxolitinib 1rucaparib 1ixabepilone 1dexamethasone acetate 1dexamethasone 21-phosphate 1dabrafenib 1cobimetinib 1cc-486 1aldesleukin 1abiraterone 1Zoledronic Acid 1Vemurafenib 1Tacrolimus 1Standard of Care 1Quality of Life 1Prednisone 1Practice Guidelines as Topic 1Patient Reported Outcome Measures 1Palliative Care 1Paclitaxel 1Moxifloxacin 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × rucaparib × Myeloid × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡